Clinical Trials Directory

Trials / Terminated

TerminatedNCT01634646

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

A Placebo-Controlled Pilot Study to Observe the Impact Lyzme5 Has on Cholesterol and Body Weight in Man

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Jeff Golini · Industry
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels in man.

Detailed description

Lyzme5 is a nutritional supplement, according to the Dietary Supplement Health and Education Act (DSHEA) of 1994. It is composed of B Vitamins along with a non-essential amino acid. The individual components of this supplement are individually Generally Recognized as Safe (have GRAS status). The manufacturer's objective was to create a nutritional supplement that would have the potential to positively impact body weight, and possibly one or more lipid value (i.e., total cholesterol, LDL, triglycerides)as well, in overweight individuals who may also have minimally elevated cholesterol levels. This observational clinical study will seek to recruit 100 volunteers in order to observe whether or not the weight-loss potential of Lyzme5, previously observed earlier in three volunteers, can be duplicated within a larger group. The second objective is to establish whether or not Lyzme5 can positively impact cholesterol levels in man.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLyzme5Dietary Supplement (or placebo): Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.). Week one: A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast; Week two: Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal; Week three through the end of the study: Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day.

Timeline

Start date
2012-05-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2012-07-06
Last updated
2013-07-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01634646. Inclusion in this directory is not an endorsement.